Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Healthcare firm...

    Healthcare firm Sundyota inks pact with Germany's Finzelberg

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-02-17T09:45:56+05:30  |  Updated On 17 Feb 2018 9:45 AM IST

    Mumbai: Healthcare firm Sundyota Numandis Group has entered into a strategic alliance with Finzelberg of Germany, to offer novel, natural healthcare products in the country.


    To start with, Sundyota will introduce ERr731, a product complimenting women's health during menopause and peri-menopause for the first time here, the company said.



    Finzelberg is a business unit of the Martin Bauer Group (Germany), a supplier of herbal and fruit infusions, medicinal teas, flavoured black and green teas, aromas, herbal powders, botanicals, herbal, fruit and tea extracts.








    As part of the pact, Sundyota Numandis will procure active ingredients from Finzelberg, undertake their formulation and development and seek registration and regulatory approvals of the same.







    This will soon be followed by commercial manufacturing along with product launch, marketing and co-marketing through promotion to doctors and other leading pharmaceutical companies in India.


    "We now have 12 international alliances to foster healthcare the natural way along with over 60 patented and exclusive therapies. Our partnership with Finzelberg will centre around knowledge-sharing to drive research and innovation," said Dinesh Kumar Arora, managing director and chief executive officer, Sundyota Numandis Group.


    According to Arora, ERr731 is safer than any currently available therapy for menopause and facilitates a smooth transition for women experiencing menopause.


    The product unveiled today aims to ease over 20 symptoms related to menopause and peri-menopause, such as hot flushes, sweating, joint and muscle pain, vaginal dryness, sleep disturbances, anxiety, low mood, irritability and works on specific beta-estrogen receptors, thus acting as a natural female hormone, he added

    Dinesh Kumar AroraERr731FinzelbergHealthcare firmMartin Bauer Groupmenopausepharmaceuticalstrategic allianceSundyota Numandis Group
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok